Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 89Observational 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Plasma cell 1Gynecologic 1Breast 1

Conditions

Multiple Myeloma 1

Interventions

Bortezomib 20Blood Specimen Collection 9Surveys and Questionnaires 8Lenalidomide 8Dexamethasone 8pomalidomide 6daratumumab 6Flow Cytometry 6Immunoenzyme Techniques 5Biopsy 5plerixafor 4idecabtagene vicleucel 4carfilzomib 4Standard of Care 4Polymerase Chain Reaction 4Amplified Fragment Length Polymorphism Analysis 4Specimen Handling 3Psychiatric Rehabilitation 3Patient Reported Outcome Measures 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Interviews as Topic 3Drug Therapy 3Data Collection 3Cytogenetic Analysis 3Chromatin Immunoprecipitation Sequencing 3talquetamab 2selinexor 2belantamab mafodotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Granulocyte Colony-Stimulating Factor × Plasma cell × Clear all
NCT00741780 2015-03-24

Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).

Sanofi

Completed
164 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡